<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>543-VITAMIN-D.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN D" code="A11CC" /></DRUG1>
<DRUG2>
<CLASS name="ANTICONVULSANT ENZYME INDUCERS" code="N03A-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of vitamin D more noticeable than in the absence of the inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Concentration dosage of vitamin D and supplementation if necessary.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>543-VITAMIN-D.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN D" code="A11CC" /></DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the absorption of the vitamin D</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>543-VITAMIN-D.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="VITAMIN D" code="A11CC" /></DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the concentrations of vitamin D more noticeable than in the absence of treatment with the rifampacin </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Concentration dosage of vitamin D and supplementation if necessary.</COMMENT>
</INTERACTION>
</INTERACTIONS>
